Categories
Category: Trends
Codex DNA partners with researchers to discover a new way to control citrus greening disease
The bacterial scourge of the citrus greening disease has affected citrus production worldwide, causing tree decline and a serious threat to Florida’s citrus industry. Citrus greening disease, or Huanglongbing (HLB), is caused by Candidotus liberibacter (CLass) and is spread by…
Great science: virtual AGBT and ABRF meetings highlight COVID-19 and more
The Codex DNA team loves to get its geek on. For the past year, we’ve missed in-person conferences, but virtual events still let us get up to speed on some of the latest advances in the scientific community. Most recently,…
Automated DNA synthesis in the spotlight at SLAS
The Codex DNA team was delighted to participate in this year’s SLAS annual conference, held by the Society for Laboratory Automation and Screening. While our favorite part of the virtual event was getting to interact with the many attendees who…
New resource: Biocompare ebook illustrates how life science tools are accelerating COVID-19 research
It can be tough to keep up on the latest COVID-19 news, but a new ebook from Biocompare is here to help. The ebook offers a nice array of articles focused on how novel tools are being used to accelerate…
Scientists use Codex DNA technology to discover fever-protective element in malaria parasite
Scientists have made a new discovery that could eventually lead to more effective treatment for malaria. In a series of experiments that included using the BioXp™ system, they determined that a key phospholipid and a related protein confer protection against…
AI-powered design tool and BioXp™ system accelerate metabolic engineering
The next industrial revolution will be biological. By turning cells into factories, synthetic biology changes how we make everything from plastic to food to medicine. But achieving those goals will require overcoming the limitations of DNA design. This is still…
Targeted mutagenesis could streamline antibody engineering
Monoclonal antibodies represent an important class of therapies for an ever-increasing number of diseases, infections, and health conditions. That’s why scientists around the world are working to improve the processes required to engineer new antibody candidates for therapeutic use. The…
Ready-made SARS-CoV-2 genomes from Codex DNA power development of vaccines, therapies, and diagnostics
Since the start of the COVID-19 pandemic, the Codex DNA team has been working hard to ensure that our customers have access to the tools they need to help in the fight against this public health scourge. We currently offer…
T cell engineering: How the BioXp™ system boosts productivity and decreases discovery time
At a recent Oxford Global NextGen Omics UK congress, our own Kirsty Maclean gave a presentation about how the BioXp™ system is powering advances in cell engineering. While she started with a high-level view of how synthetic biology applies to…
Cellibre scientists accelerate enzyme engineering with Codex DNA collaboration
One of the most popular applications of synthetic biology is to confer desired traits to an organism. Designing a range of possibilities and then testing each one for fitness, productivity, stability, or some other goal is critically important as the…
In pandemics, rapid DNA synthesis accelerates vaccine development
Back in 2013, I played a small role in response to what then seemed like the next potential pandemic — an outbreak of H7N9, an avian influenza virus. At the time, I was working with Novartis scientists, and we were…
Synthetic biology makes a difference in drug discovery
If you were there for the early days of synthetic biology, you probably remember it the way we do: a relatively small number of academic scientists toiling in labs to build key parts, like toggle switches, and tinkering with the…
Scientists develop nanobody treatments with the BioXp™ system
In the age of COVID-19, there has been a ton of scientific interest in nanobodies, or single-domain antibodies that can be used for finely targeted viral vaccines. It’s also been a hot topic among users of our BioXp™ system —…
Codex DNA celebrates Breast Cancer Awareness Month with great science
Breast cancer is now recognized as the most common malignancy worldwide among women, irrespective of age. Today’s standard of care and breast cancer management relies heavily on chemotherapy, hormone therapy, and targeted therapy. However, there is still much to be…
Highlights from the SynBioBeta 2020 Conference
The Codex DNA team really enjoyed attending this year’s virtual Global Synthetic Biology Conference hosted by SynBioBeta. If you missed the event, we’ve got you covered — here’s our take on highlights from the meeting. BioXp™ system in the spotlight…
Webinar: Rapid synthesis speeds immunotherapy development
For cancer patients with few other treatment options, the need for new targeted immunotherapies is genuinely a matter of life or death. So how to accelerate the development of new therapies? One key component is automated DNA synthesis. That was…
At Oxford conference, automated synthetic biology was in the spotlight
For BioXp™ system users, antibody drug discovery is one of the most popular applications. That’s why we were delighted to participate in the recent Oxford Global Biologics virtual conference, with a presentation from our own Kirsty Maclean, Director of Applications…
Biotech scientists use BioXp™ system to streamline antibody drug discovery
Several recent publications from the rockstar team at GigaGen illustrate how they are using the BioXp™ system to streamline antibody drug discovery workflows. It’s tough to overstate the importance of this area of research: monoclonal antibodies, antibody drug conjugates, and…